Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York Times

AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal

AstraZeneca pairs with Insitro on a $1.5B AI collaboration to advance drug targets for MASH and heart conditions.

AstraZeneca Entered Strategic Drug Discovery Collaboration, Licensing Agreement With Insitro To Use Advanced AI Systems To Identify Novel Drug Targets, Develop Therapeutics For MASH, Cardiomyopathies

Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $132

Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $136 to $132.

9 Of 11 Sectors Rise In Friday Trading As Cyclicals Lead

Nine of 11 sectors are higher in Friday’s regular session, with cyclical sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.

This Unstoppable Vanguard ETF Could Turn $500 Per Month Into $1 Million Over the Long Term

The Vanguard S&P 500 Growth ETF (VOOG) tracks the S&P 500 Growth index of 151 best-performing growth stocks, heavily weighted toward AI and technology companies. With a 16.9% compound annual return since 2010 and 28.4% over the last three years, consistent $500 monthly investments could potentially reach $1 million in approximately 23 years, even at conservative 14.1% annual returns.

Committee For Medicinal Products For Human Use Recommends Approval Of Indication Extension Of Johnson & Johnson's TALVEY To Treat Adults With Relapsed Or Refractory Multiple Myeloma

https://www.jnj.com/media-center/press-releases/chmp-recommends-approval-of-johnson-johnsons-talvey-talquetamab-plus-daratumumab-in-earlier-line-treatment-of-relapsed-refractory-multiple-myeloma